Last reviewed · How we verify
Thymic peptides
At a glance
| Generic name | Thymic peptides |
|---|---|
| Also known as | Unicahsina |
| Sponsor | Universidad Católica de Honduras |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- HLA-Identical Sibling Renal Transplant Tolerance (NA)
- Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders (PHASE2)
- Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma or Thymic Carcinoma (PHASE2)
- Renal Allograft Tolerance Through Mixed Chimerism - SMC/MGH (PHASE1)
- Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Thymic Cancer That Cannot Be Removed by Surgery (PHASE2)
- Tolerance Through Mixed Chimerism (Sip-Tego) (EARLY_PHASE1)
- Nivolumab and DA-EPOCH-R in Pediatric Primary Mediastinal (Thymic) Large B-cell Lymphoma (PHASE1, PHASE2)
- Expanded Access Protocol Thymus Transplantation (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Thymic peptides CI brief — competitive landscape report
- Thymic peptides updates RSS · CI watch RSS
- Universidad Católica de Honduras portfolio CI